Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeSales of Property, Plant and EquipmentSales of Property, Plant and EquipmentShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationLeasesLong-Term Debt RepaymentsOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetShares IssuedShares OutstandingShares Outstanding
Ratios

Editas Medicine (EDIT) Long-Term Debt Issuances (2015)

Editas Medicine (EDIT) reported Long-Term Debt Issuances of $709000.0 for Q3 2015, down 10.37% on a QoQ basis from $791000.0 in Q1 2015.

Editas Medicine (EDIT) has 1 years of Long-Term Debt Issuances data on file, last reported at $709000.0 in Q3 2015.

  • Quarterly Long-Term Debt Issuances changed N/A year-over-year to $709000.0 in Q3 2015, while the trailing twelve-month figure through Dec 2015 was $1.5 million (changed N/A YoY) and the FY2024 annual result came in at $57.0 million, changed N/A from the prior year.
  • Long-Term Debt Issuances declined to $709000.0 in Q3 2015 per EDIT's latest filing, from $791000.0 in the prior quarter.
  • Across five years, Long-Term Debt Issuances topped out at $791000.0 in Q1 2015 and bottomed at $709000.0 in Q3 2015.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Long-Term Debt Issuances (Qtr)
1 Quantum Biopharma 1,216,509.61 Bn 1,216,509.61 Bn - 2.73 Mn
2 Alterity Therapeutics 764,224.41 Bn 764,224.38 Bn - -
3 Legend Biotech 2,716.00 Bn 2,715.71 Bn 242.10 Mn -
4 Nanobiotix 2,248.83 Bn 2,248.77 Bn - -
5 Akari Therapeutics 1,951.18 Bn 1,951.17 Bn - -
6 Vertex Pharmaceuticals 113.69 Bn 106.44 Bn 2.59 Bn -
7 Evaxion A 64.16 Bn 64.14 Bn - -
8 Regeneron Pharmaceuticals 63.94 Bn 55.18 Bn 3.31 Bn -
9 Alnylam Pharmaceuticals 40.13 Bn 37.12 Bn 959.66 Mn -
10 Editas Medicine 338.62 Mn 338.62 Mn - -

Historic Data

Download Data 🔒
DateValue
Sep 30, 2015 709,000.00
Sep 30, 2015 709,000.00
Mar 31, 2015 791,000.00
Mar 31, 2015 791,000.00